Amgen's $15.73 Billion Trading Volume Surges 54.85% to 101st Place Amid FDA Approval of UPLIZNA for Rare Autoimmune Disorder

On April 4, 2025, Amgen's trading volume reached $15.73 billion, marking a 54.85% increase from the previous day, placing it at the 101st position in the day's stock market rankings. Amgen's stock price fell by 4.99%.

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD), a chronic condition with significant unmet medical needs. This approval highlights UPLIZNA's potential to significantly reduce disease flares and reliance on corticosteroids, offering a new treatment avenue for this rare autoimmune disorder.

Following the FDA approval, UPLIZNA became the first and only drug approved for the treatment of IgG4-RD. This breakthrough CD19+ B-Cell targeted therapy has shown sustained efficacy with twice-yearly dosing in the Phase 3 MINT trial for generalized myasthenia gravis, further solidifying its potential in the market.